The next triggers in Covid-19 vaccine development
Pfizer/Biontech’s preprint might prove academic as investors look to pivotal study designs and readouts.
Moderna shows the value of bulk-buying
The new price for its Covid-19 vaccine is lower than earlier deals – but arguably not by much.
Covid-19 vaccines remain hot – in spite of Inovio
Biontech and Pfizer come roaring back with the first human data on BNT162, a day after Inovio’s effort disappointed.
What to look for in upcoming Covid-19 trial readouts
Industry-sponsored clinical studies against the new coronavirus have proliferated, as have their designs and efficacy measures.
